Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin.
Angiogenesis Inhibitors
/ administration & dosage
Animals
Collagen
/ metabolism
Extracellular Matrix Proteins
/ administration & dosage
Half-Life
Humans
Intravitreal Injections
/ methods
Male
Mass Spectrometry
/ methods
Neovascularization, Physiologic
/ drug effects
Proteoglycans
/ administration & dosage
Rabbits
Retina
/ metabolism
Vitreous Body
/ metabolism
SLRP
intravitreal pharmacokinetics
neovascularization
opticin
selected reaction monitoring mass spectrometry
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
06 07 2020
06 07 2020
Historique:
pubmed:
22
5
2020
medline:
8
6
2021
entrez:
22
5
2020
Statut:
ppublish
Résumé
Opticin is an endogenous vitreous glycoprotein that may have therapeutic potential as it has been shown that supranormal concentrations suppress preretinal neovascularization. Herein we investigated the pharmacokinetics of opticin following intravitreal injection in rabbits. To measure simultaneously concentrations of human and rabbit opticin, a selected reaction monitoring mass spectrometry assay was developed. The mean concentration of endogenous rabbit opticin in 7 uninjected eyes was measured and found to be 19.2 nM or 0.62 μg/mL. When the vitreous was separated by centrifugation into a supernatant and collagen-containing pellet, 94% of the rabbit opticin was in the supernatant. Intravitreal injection of human opticin (40 μg) into both eyes of rabbits was followed by enucleation at 5, 24, and 72 h and 7, 14, and 28 days postinjection (
Identifiants
pubmed: 32437164
doi: 10.1021/acs.molpharmaceut.0c00151
pmc: PMC7341526
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Extracellular Matrix Proteins
0
OPTC protein, human
0
Proteoglycans
0
Collagen
9007-34-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2390-2397Subventions
Organisme : Medical Research Council
ID : MR/M025365/1
Pays : United Kingdom
Références
Curr Eye Res. 2012 Dec;37(12):1171-4
pubmed: 22991959
J Biol Chem. 2003 Nov 14;278(46):45280-7
pubmed: 12951322
Br J Ophthalmol. 2004 May;88(5):697-702
pubmed: 15090426
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):567-73
pubmed: 24398088
J Biol Chem. 2000 Jan 21;275(3):2123-9
pubmed: 10636917
Eye (Lond). 2002 Jul;16(4):454-60
pubmed: 12101453
Exp Eye Res. 2015 Aug;137:111-24
pubmed: 25975234
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Invest Ophthalmol Vis Sci. 2012 Nov 07;53(12):7528-38
pubmed: 23074202
Methods. 2005 Mar;35(3):265-73
pubmed: 15722223
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2202-10
pubmed: 11527931
Mol Cell Proteomics. 2013 Nov;12(11):3319-29
pubmed: 23997015
Eye (Lond). 2015 Apr;29(4):561-8
pubmed: 25592118
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):228-34
pubmed: 22159013
Ophthalmology. 2007 Dec;114(12):2179-82
pubmed: 18054637
Crit Rev Anal Chem. 2019;49(2):126-137
pubmed: 30821472
J Biol Chem. 2012 Aug 10;287(33):28027-36
pubmed: 22669977
Mol Cell Proteomics. 2013 Nov;12(11):3148-59
pubmed: 23897580
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
Clin Biochem. 1997 Aug;30(6):455-63
pubmed: 9316739
Matrix Biol. 2015 Mar;42:11-55
pubmed: 25701227
AMA Arch Ophthalmol. 1957 Jan;57(1):85-9
pubmed: 13381239